INTRODUCTION
============

Male hypogonadism (HG) is a medical condition characterized by a failure of the testis to produce and release adequate concentrations of its products, *i.e.*, sperms and sex steroids. It can be congenital or acquired. The latter form is far more common than the former and it is usually apparent during adulthood \[[@B1]\]. Adult-onset HG is mainly related to aging itself and to the presence of comorbid conditions, increasingly more prevalent in ageing men, which-might impair the regular functioning of the testis and of its controllers, such as the pituitary (follicular stimulating hormone \[FSH\] and luteinizing hormone \[LH\]) and hypothalamus (gonadotropin-releasing hormone \[GnRH\]) \[[@B2][@B3][@B4]\]. Among these potentially impairing conditions, there are metabolic disturbances which are very common in the general population, such as obesity, metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) \[[@B1][@B4][@B5][@B6]\]. The mechanisms by which an altered metabolism could impair the hypothalamic-pituitary-gonadal axis is still unclear, but the possibility that a low-grade hypothalamic inflammation can cause a disruption in GnRH formation or action is growing \[[@B7]\]. Adult-onset HG- or more commonly defined late-onset hypogonadism (LOH) is a condition characterized by a constellation of unspecific symptoms and signs, often superimposable to those of the aging process *per se*. Among those, sexual dysfunctions appear as the mostly specific symptoms characterizing the androgen deficiency. In fact, there is considerable evidence that testosterone (T) plays a crucial role in regulating male sexual function \[[@B8][@B9][@B10][@B11]\]. The European Male Aging Study (EMAS), a population based survey performed on more than 3,400 men recruited from 8 European centres, has clearly shown that sexual symptoms---*i.e.*, decreased frequency of sexual thoughts, decreased morning erections, and erectile dysfunction (ED)---are the most sensitive and specific symptoms in identifying patients with low T \[[@B12]\]. Similar results have been more recently reported by the T Trials \[[@B13]\], a randomized controlled trial performed in 788 community-dwelling men recruited from 12 sites in the United States, and by Rastrelli et al \[[@B14]\] in a large sample of men seeking medical care for sexual dysfunction. It has been proposed that when the presence of sexual symptoms is associated with a biochemical deficiency of circulating T a diagnosis of symptomatic LOH can be made. In the European adult population, 2% of the sample satisfy these criteria, whereas 17% demonstrated an isolated T deficiency (total T \<11 nmol/L) \[[@B12]\].

As in all endocrine disorders, the goal of treatment of HG is to restore the deficient glandular function. If fertility is the issue and the testis is under-stimulated because of a gonadotropin deficiency, FSH and LH administration is recommended. In all the other cases, testosterone therapy (TTh) is the most convenient choice \[[@B15]\]. Quite surprisingly, in the United States, after a 2015 Food and Drug Administration (FDA) position statement (<http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm>), TTh is approved only for congenital HG or for acquired forms due to an "organic" damage to the brain centres or to the testis. Hence, either comorbidity-associated or age-related HG are not recognized as true pathological conditions needing a pharmacological intervention. The recently published Guidelines of the Australian Endocrine Society \[[@B16]\] fully endorsed the FDA\'s position, suggesting that removing the underlying metabolic conditions, such as losing weight, must be the optimal therapeutic strategy for treating obesity-associated HG, and that TTh is not justified in such conditions. Hence, the concept that a distinction between a true HG (classicor organic HG) and a false, age-related, HG (the so-called low T syndrome or andropause or pseudohypogonadism) is raising \[[@B16]\]. It is interesting to note that among more than 4,000 subjects seeking medical care at an endocrine unit for sexual dysfunction, we found a large proportion of HG subjects (*i.e.*, 20%, defined as total T below 10.4 nmoles/L \[[@B17]\]). Of this, only 15% of all causes of HG fulfil the criteria of "classic HG", whereas the large majority presents comorbidities, including obesity, MetS and T2DM \[[@B17]\]. According to the FDA\'s position and the Australian recommendations, all these symptomatic HG subjects should be left untreated, with a pharisaic advice of conducting a healthier lifestyle. Scepticism and even reluctance to start an androgen supplementation is essentially based on two kinds of considerations regarding TTh: 1) lack of efficacy in non-organic HG and 2) side effects. In this review we will analyse evidence underlying these believes.

LACK OF EFFICACY OF TESTOSTERONE THERAPY IN NON-ORGANIC HYPOGONADISM
====================================================================

There is no controversy about the fact that losing weight is an effective strategy to overcome T deficiency in obese subjects. In a previous meta-analysis we demonstrated that either lifestyle changes or bariatric surgery are effective in raising gonadotropin and T secretion \[[@B1][@B18]\]. Besides male HG, T2DM is another obesity-associated medical condition with a growing prevalence in the general population worldwide \[[@B19]\]. Also for T2DM, weight reduction and change in lifestyle are the frontline therapy, but it is inconceivable to negate effectiveness of pharmacological antidiabetic intervention just because the diabetic patient is also obese \[[@B19]\]. In fact, metformin administration is strongly suggested in newly diagnosed T2DM, regardless of any lifestyle intervention \[[@B19]\]. Why, along with lifestyle changes, is pharmacological treatment with metformin advised in T2DM and TTh is not in HG? Maybe because T2DM is a more "organic" condition than HG? It is interesting to note that the well-defined organic conditions leading to diabetes represent less than 1% of all cases of diabetes \[[@B19]\]. All the other cases are multi-factorial conditions that may or may not have a genetic background, still largely unidentified. This does not mean that diabetes exists in all cases or that it should not be promptly treated. Similarities between T2DM and male HG are schematized in [Table 1](#T1){ref-type="table"}.

The fact that symptoms of androgen deficiency in adulthood often overlap with those characteristics of the aging process (and its associated comorbidities) further complicates the debate. However, T2DM also is a condition characterized by unspecific symptoms, often overlapping with those of the aging process ([Table 1](#T1){ref-type="table"}). Interestingly, criteria for diagnosis of diabetes are based only on well-defined alterations of biochemical parameters, such as increased glycaemia or HbA1c, independently of symptoms \[[@B19]\]. This is not the case of HG. In fact, in LOH, all the Scientific Societies indicate that a reduction of circulating T is not enough for defining the disease. Specific symptoms must be present along with T deficiency. Symptoms of androgen deficiency include psychological (*i.e.*, depression), physical (*i.e.*, fatigue) and sexual concerns \[[@B20][@B21][@B22]\]. Recently, Millar et al \[[@B23]\], reported a review of available literature to estimate the accuracy and operating characteristics of signs and symptoms for predicting low T in aging men. They found a weak correlation between signs, symptoms and T levels, uncertainty about what threshold T levels should be considered low for aging men and wide variation in estimated prevalence of the condition \[[@B23]\]. In addition, all relationships with symptoms are relatively poor in terms of sensitivity and specificity. However, as stated before, the EMAS study has clearly shown that sexual symptoms, and in particular their syndromic association, allow a better identification of the so-called LOH \[[@B12][@B24]\]. Similar results were recently reported by us in a large cohort (n=4,890) of subjects consulting for ED at the University of Florence (UNIFI) \[[@B14]\]. However, in both the EMAS \[[@B12]\] and UNIFI \[[@B14]\] cohorts, Loess curve analysis did not indicate a clear-cut threshold where the association between sexual symptoms and hormonal deficiency is apparent, with a total T below 11 and 10.4 nmoles/L being the best indicators of sexual symptomatology, respectively. In contrast, in the EMAS study \[[@B12]\], the relationship between T deficiency and psychological and physical symptoms was rather poor or even absent.

Considering that sexual symptoms are the most genuine correlates of T deficiency, it is interesting to evaluate whether or not treating this deficiency is able to restore sexuality. If this is the case, we have the scientific demonstration that the so-called LOH does exist according to an "ex-juvantibus" criterion. A recent systematic qualitative review on the effect of TTh on several outcomes concluded that T did not show consistent benefit for sexual function \[[@B25]\]. However, the same Authors declared that sexual function was evaluated using different tools \[[@B25]\]. In addition, they included both eugonadal and hypogonadal subjects in the analysis \[[@B25]\]. Hence, their conclusions (based only on a personal perspective) are not derived from validated statistical methods. In contrast with the last report, we previously documented, using a meta-analytic method, that TTh is superior, when compared to placebo, in improving all aspects of sexual function \[[@B26]\]. [Table 2](#T2){ref-type="table"} summarizes the main results of the meta-analysis. The outcomes observed were independent of age but indirectly related to the levels of T at enrolment. Furthermore, as expected, the effects of TTh were lower in the presence of vascular damage, such as in the case of T2DM \[[@B26]\]. Considering that metabolic conditions are often associated with relatively milder forms of T deficiency, it is possible that a lower apparent efficacy of TTh in T2DM is due to higher T baseline levels \[[@B27]\]. In addition, the mitigated effect of TTh in T2DM is also in line with the lower efficacy of all available treatment for ED in subjects with diabetes, due to the presence of the diabetes-associated chronic complications, which are not necessarily due to an androgen deficiency \[[@B21][@B22][@B28][@B29]\]. Although the presence of metabolic derangements could limit the efficacy of TTh on ED, the positive effect of TTh on body composition and insulin sensitivity \[[@B30][@B31][@B32]\] might counterbalance the lower efficacy. Our meta-analysis confirmed epidemiological observation showing that sexual dysfunctions are a hallmark of HG, because TTh can significantly improve them. The vast majority of the subjects enrolled in the included RCTs are not those with "classic" HG. For example, in the T trial \[[@B33]\] 63% of the participants were obese and all were 65 years or older without apparent reason for HG other than age. In conclusion, there is robust evidence that all the forms of symptomatic HG should be treated irrespective to their "organic" or "non-organic" (metabolic) origin because most specific symptoms (sexual ones) are improved.

LONG TERM SAFETY OF TESTOSTERONE THERAPY
========================================

T esters have been available for almost 80 years; however, only over the past two decades has the introduction and use of newer, user-friendly preparations dramatically expanded the market \[[@B4]\]. Since their introduction to the market, the risk of prostate cancer (PC) was considered the most feared side effect related to the use of T preparations. In addition, quite recently,conflicting data have raised the possible relationship between TTh and increased cardiovascular (CV) risk. In the following section, these two aspects will be analyzed in detail.

1. Cardiovascular events during testosterone therapy
----------------------------------------------------

Over the last four years, there have been mounting concerns that TTh may increase the risk for CV events, such as heart attacks and strokes. These concerns were essentially based on two retrospective pharmaco-epidemiological papers published between the end of 2013 and the beginning of 2014 \[[@B34][@B35]\]. Salient pitfalls related to these reports have been commented elsewhere \[[@B17][@B36][@B37]\]. Although these studies presented many flaws, due to their retrospective design and to the little information on the databases, they received much attention in the lay media, including The New York Times. Other studies report that low T levels in older men are associated with increased CV risk and that TTh may have CV benefits \[[@B17][@B36][@B37]\]. In particular, besides the two aforementioned observational studies, several other reports were published either previously or thereafter \[[@B34][@B35][@B38][@B39][@B40][@B41][@B42][@B43][@B44][@B45][@B46][@B47][@B48]\]. Overall, 13 studies have been published so far, including 194,609 cases and 1,195,582 controls ([Table 3](#T3){ref-type="table"}). Among them, six studies compared the effect of TTh in HG men *vs*. untreated HG men. In the other seven studies, the effect of T prescription was compared to subjects who were not prescribed T. In the latter cases limited information regarding the T levels was available ([Table 3](#T3){ref-type="table"}). Overall, an increased CV risk was reported only in the Vigen et al \[[@B34]\] and Finkle et al \[[@B35]\] whereas in all other reports a neutral or beneficial effect of TTh was found ([Table 3](#T3){ref-type="table"}). In particular, in 2017 the largest observational study published so far became available \[[@B48]\]. The study evaluated 44,335 male patients at Kaiser Permanente medical centers in Northern and Southern California who had been diagnosed with androgen deficiency between January 1, 1999 and December 31, 2010. Of these, 8,808 men were treated with TTh, whereas 35,527 were never dispensed T. Among men with androgen deficiency, those who were dispensed T prescriptions were associated with a lower risk of CV outcomes overa median follow-up of 3.4 years. Despite their strengths, observational studies present important limitations including: selection, information, and confounding biases. In addition, usually limited information regarding the level of T before and during TTh are available. Hence, caution is needed when evaluating results reporting small differences.

Systematic reviews and meta-analyses are often considered as the highest level of evidence for evaluating interventions in healthcare and as a particularly useful tool to address questions for which multiple data sources are conflicting. Eight systematic meta-analyses on the association between TTh and CV risk have been published so far ([Table 4](#T4){ref-type="table"}) \[[@B49][@B50][@B51][@B52][@B53][@B54][@B55][@B56]\]. The number of included trials ranged from 19 to 75 including from 1,084 to 5,464 subjects. Seven meta-analyses \[[@B49][@B50][@B52][@B53][@B54][@B55][@B56]\] reported outcomes on aggregate CV events, whereas one \[[@B51]\] investigated disaggregate events. Forest plots of estimated odds ratio (95% confidence intervals) for aggregate or disaggregate CV events, as derived from available meta-analyses investigating the effects of TTh on CV risk, are summarized in [Fig. 1](#F1){ref-type="fig"}. Only Xu et al \[[@B52]\] reported an increased CV risk related to TTh. However, it is important to emphasize that the latter authors used, for their analysis, "composite CV-related events", including all investigator-reported adverse events assigned to the CV system. Hence, cases of "peripheral edema" and "self-reported syncope" were also allocated to the category CV events, leading to an artificial increase of the overall number of events \[[@B52]\]. Conversely, all other meta-analyses published so far did not report an increased CV risk related to TTh either when aggregated or disaggregate CV were considered ([Fig. 1](#F1){ref-type="fig"}). It is important to recognize that all available trials included in the meta-analyses have a relatively short duration, lasting atmost three years. Therefore, although there is no clear sign of risk in the short term, no information is available on possible long-term effects.

2. Prostate safety
------------------

Prostate safety remains one of the most important controversial issues of TTh since, historically, PC has been associated with an increased androgenicity \[[@B57][@B58]\]. Hence, clinicians and regulatory agencies are all concerned by the fact that TTh could cause or promote PC.

Much evidence published in the two last decades has substantially better clarified the role of T in regulating prostate growth and differentiation \[[@B57][@B58][@B59][@B60][@B61]\]. Epidemiological studies have failed to find an association between endogenous T levels and risk of PC. In particular, the most recent meta-analysis---that pooled worldwide data from 20 prospective studies including 5,623 PC cases and 14,604 controls and mean follow-up of 10 years---reports a relative risk of PC of 0.99 \[0.96;1.02\] for an increase of 5 nmol/L of T \[[@B62]\].

In line with these data it has been demonstrated that androgen-dependency of prostate growth is evident only in the hypogonadal condition, but not in the eugonadal state. In fact, according to Morgentaler and Traish\'s "saturation hypothesis", the human prostate androgen receptors are "saturated" by the circulating androgens and therefore rather insensitive to further T increase, such as those derived from TTh in cases of mild HG \[[@B63]\]. Accordingly, *in vitro* studies have documented that prostate cell proliferation increased at low T concentration but at higher concentrations even logarithmic increases in T could not enhance growth \[[@B58]\]. This observation can explain the positive effect of androgen deprivation therapy (ADT) in androgen sensitive advanced PC and the possible recurrence as the androgen levels normalize from castrated levels after treatment \[[@B58]\].

The aforementioned evidence was further confirmed by the analysis of interventional trials. Since 2005, seven systematic meta-analyses on the association between TTh and prostate safety are available and their results are summarized in [Table 5](#T5){ref-type="table"} \[[@B49][@B51][@B62][@B64][@B65][@B66][@B67]\]. The number of trials considered ranged from 4 to 26 including from 1,084 to 5,464 subjects. As expected, TTh was associated with a significant short term increase in prostate-specific antigen (PSA) levels \[[@B64][@B65]\] or prostate volume ([Fig. 2](#F2){ref-type="fig"}) \[[@B67]\]. Accordingly, we previously demonstrated that low PSA could be considered a reliable biochemical marker of reduced bioactive circulating androgens in subjects consulting for sexual dysfunction, providing an index of low androgenization, which includes T-activated post-receptor downstream events \[[@B68][@B69]\]. No increased risk in International prostate symptom score (IPSS) worsening, in detection of abnormal PSA levels or in developing PC was observed ([Fig. 2](#F2){ref-type="fig"}). Interestingly, by evaluating data from observational studies based on the use of long-term injectable T undecanoate, we previously observed an improvement of IPSS, particularly when the analysis was restricted to those studies enrolling only hypogonadal subjects at enrolment \[[@B32]\]. In the last few years, we have produced both experimental and clinical data suggesting a link between reduced T levels, prostate inflammation and benign prostatic hyperplasia (BPH) \[[@B59][@B60][@B61]\]. The underlying pathogenetic mechanisms are not completely understood, but an intriguing hypothesis indicates a close link between obesity and its related metabolic derangement (particularly dyslipidemia), reduced T and an increased risk of BPH and its related inflammatory component \[[@B59][@B60][@B61][@B70]\].

CONCLUSIONS
===========

A large body of evidence has documented that sexual symptoms are the most specific correlates of T deficiency. TTh is able to improve all aspects of sexual function independent of the pathogenetic origin of the disease supporting the scientific demonstration that the so-called LOH does exist according to an "ex-juvantibus" criterion. Although the presence of metabolic derangements could mitigate the efficacy of TTh on ED, the positive effect of TTh on body composition and insulin sensitivity might counterbalance the lower efficacy. CV safety concerns related to TTh are essentially based on a limited number of observational and randomized controlled trials which present important methodological flaws. When HG is properly diagnosed and TTh correctly performed no CV and prostate risk have beendocumented.
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###### Similarities between T2DM and LOH

![](wjmh-35-65-i001)

  Variable                                                  T2DM      LOH
  --------------------------------------------------------- --------- ---------
  Prevalence (%)                                            2\~15     2\~15
  Association with aging                                    Yes       Yes
  Association with obesity                                  Yes       Yes
  Association with sexual dysfunction                       Yes       Yes
  Symptom specificity                                       No/mild   No/mild
  Biochemical threshold for definition                      Yes       Yes
  Well-known (genetic or organic) etiological factors (%)   1         15
  Improved by weight loss or lifestyle changes              Yes       Yes
  Improved by a specific therapy                            Yes       Yes

T2DM: type 2 diabetes mellitus, LOH: late-onset hypogonadism.

###### Effect size (with 95% confidence interval) in several sexual parameters across randomized controlled trials evaluating the effect of testosterone treatment *vs*. placebo

![](wjmh-35-65-i002)

  Sexual parameter                                No. of trials included   No. of patients included   Outcome
  ----------------------------------------------- ------------------------ -------------------------- ---------------------------
  Erectile function component                                                                         
   Overall erectile function component^a^         24                       1,473                      0.82 \[0.47\~1.17\]^\*^
   Overall sexual-related function component^b^   19                       1,341                      0.75 \[0.37\~1.12\]^\*\*^
   Sleep-related erections                        10                       436                        0.87 \[0.47\~1.27\]^\*\*^
  Libido component                                                                                    
   Overall libido component                       17                       1,111                      0.81 \[0.47\~1.17\]^\*\*^
  Orgasm component                                                                                    
   Overall orgasmic component                     10                       677                        0.68 \[0.34\~1.02\]^\*\*^
  Other sexual parameters                                                                             
   Frequency of intercourse                       10                       327                        0.75 \[0.33\~1.16\]^\*\*^
   Overall sexual satisfaction                    9                        618                        0.80 \[0.41\~1.20\]^\*\*^
   Overall sexual function                        10                       990                        0.67 \[0.22\~1.12\]^\*\*^

^\*^*p*\<0.001, ^\*\*^*p*\<0.0001. ^a^Including coital and non coital erections; ^b^Only coital erections considered.

Adapted from Corona G et al (J Sex Med 2014;11:1577-92) \[[@B26]\].

###### Descriptive characteristics of the available pharmaco-epidemiological studies evaluating the impact of testosterone treatment on forthcoming overall mortality or myocardial infarction

![](wjmh-35-65-i003)

  Study                                   Age (y)^a^   Number (case/control)   Follow-up (wk)   Diagnosis of hypogonadism                            Study design                               Adjusted overall mortality   Adjusted acute mycardial infarction
  --------------------------------------- ------------ ----------------------- ---------------- ---------------------------------------------------- ------------------------------------------ ---------------------------- -------------------------------------
  Shores et al (2012) \[[@B38]\]          62.1         398/633                 81               TT \<250 ng/dL (8.7 nmol/L)                          T treatment vs. no treatment               ↓                            NA
  Finkle et al (2014) \[[@B35]\]          54.3         55,593/141,031          140              NA                                                   TTh prescription vs. PDE5i prescription    NA                           ↑
  Muraleedharan et al (2013) \[[@B39]\]   45\~59                               16.5             TT \<300 ng/dL (10.4 nmol/L)                         T treatment vs. no treatment               ↓                            NA
  Vigen et al (2013) \[[@B34]\]           63.4         1,223/7,486             110              TT \<300 ng/dL (10.4 nmol/L)                         T treatment vs. no treatment               ↑b                           ↑b
  Baillargeon et al (2014) \[[@B40]\]     ≥66          6,355/19,065            182              NA                                                   TTh prescription vs. no TTh prescription   NA                           ↔
  Eisenberg et al (2015) \[[@B41]\]       54.4         284/225                 520              NA                                                   TTh prescription vs. no TTh prescription   ↔                            NA
  Etminan et al (2015) \[[@B42]\]         70.4         30.066/120.264          145              NA                                                   TTh prescription vs. no TTh prescription   NA                           ↔
  Ramasamy et al (2015) \[[@B43]\]        74.3         153/64                  191              TT \<300 ng/dL (10.4 nmol/L)                         T treatment vs. no treatment               ↔                            NA
  Sharma et al (2015) \[[@B44]\]          66.2         60.632/21.380           304              TT lower than the local laboratory reference range   T treatment vs. no treatment               ↓^c^                         ↓^c^
  Tan et al (2015) \[[@B45]\]             20\~86       19.968/821.725          72               TT \<350 ng/dL (12.0 nmol/L)                         TTh prescription vs. no TTh prescription   NA                           ↓
  Maggi et al (2016) \[[@B46]\]           59.1         759/249                 156              TT lower than the local laboratory reference range   T treatment vs. no treatment               ↔                            ↔
  Wallis et al (2016) \[[@B47]\]          ≥65          10.311/28.029           260              NA                                                   TTh prescription vs. no TTh prescription   ↓                            NA
  Cheetham et al (2017) \[[@B48]\]        58.4         8,808/35,527            158 (median)     Mixed hypogonadanal and eugonaladl subjcts           T treatment vs. no treatment               ↓d                           ↓d

TT: total testosterone, NA: not available, T: testosterone, TTh: testosterone therapy, PDE5i: phosphodiesterase type 5 inhibitor, ↓: reduced risk, ↑: increased risk, ↔: unchanged risk.

^a^Values are presented as mean only or mean range

^b^Composite of all-cause mortality, acute myocardial infarction, and ischemic stroke.

^c^Composite cardiac events= myocardial infarction, coronary revascularization, unstable angina, and sudden cardiac death.

^d^Normalized treated *vs*. untreated.

###### Comparisons of the available meta-analyses evaluating the relationship between testosterone therapy and CV risk

![](wjmh-35-65-i004)

  Variable                                      Study                                                                                                  
  --------------------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ----- ---- ----- ---- ----- ---- ----- ----
  No. of trials included                        19      30      51      27      75      35      45      39                                             
  No. of patients analyzed                      1,084   1,642   2,679   2,944   5,464   3,703   5,328   5,441                                          
  Inclusion criteria                            Yes     No      Yes     No      Yes     No      Yes     No      Yes   No   Yes   No   Yes   No   Yes   No
   Primary end point MACE incidence                     ×               ×               ×               ×       ×                ×          ×          ×
   Primary end point CV event other than MACE   ×               ×               ×               ×                     ×    ×          ×          ×     
   Time restriction (\>12 wk)                   ×                       ×               ×               ×             ×          ×          ×          ×
   Age restriction (≥45 y)                      ×                       ×               ×               ×             ×          ×          ×          ×
  CV event analysis                                                                                                                                    
   All CV events                                ×               ×                       ×       ×               ×          ×          ×                ×
   Serious adverse events                               ×               ×               ×       ×                     ×          ×          ×          ×
   (including MACE)                                                                                                                                    
   MACE                                                 ×               ×               ×               ×       ×                ×          ×          ×
   AMI                                          ×               ×               ×                       ×       ×                ×          ×    ×     
   Acute coronary syndrome                      ×                       ×               ×               ×       ×                ×          ×          ×
   Coronary by-pass surgery                     ×                       ×       ×                       ×       ×                ×          ×          ×
   Stroke                                       ×                       ×               ×               ×       ×                ×          ×    ×     
   New heart failure                                    ×               ×               ×               ×       ×                ×          ×          ×
   Arrhythmias                                  ×                       ×       ×                       ×       ×                ×          ×          ×
   CV mortality                                         ×               ×               ×       ×               ×                ×          ×          
   Overall mortality                                    ×               ×               ×               ×             ×          ×          ×    ×     

X indicates if Yes or No. CV: cardiovascular, MACE: major adverse cardiovascular events, AMI: acute myocardial infarction.

###### Comparisons of the available meta-analyses evaluating the relationship between testosterone therapy and prostate safety

![](wjmh-35-65-i005)

  Variable                                      Calof et al (2005) \[[@B49]\]   Fernández-Balsells et al (2010) \[[@B51]\]   Cui and Zhang (2013) \[[@B64]\]   Cui et al (2014) \[[@B65]\]   Guo et al (2016) \[[@B67]\]   Kang et al (2015) \[[@B66]\]   Boyle et al (2016) \[[@B62]\]                                    
  --------------------------------------------- ------------------------------- -------------------------------------------- --------------------------------- ----------------------------- ----------------------------- ------------------------------ ------------------------------- ---- ----- ---- ----- ---- ----- ----
  No. of trials included                        19                              51                                           16                                22                            16                            15                             27                                                               
  No. of patients analyzed                      1,084                           2,679                                        1,030                             2,351                         1,921                         1,124                          2,213                                                            
  Inclusion criteria                            Yes                             No                                           Yes                               No                            Yes                           No                             Yes                             No   Yes   No   Yes   No   Yes   No
   Primary end point prostate safety                                            ×                                                                              ×                             ×                                                            ×                                          ×          ×    ×     
   Data presented according to trial duration                                   ×                                                                              ×                             ×                                                            ×                                          ×          ×          ×
   Time restriction (\>12 wk)                   ×                                                                                                              ×                                                           ×                                                              ×          ×          ×          ×
   Time restriction (\>24 wk)                                                   ×                                                                              ×                                                           ×                                                              ×    ×                ×          ×
   Age restriction (≥45 yr)                     ×                                                                                                              ×                                                           ×                                                              ×          ×          ×          ×
  Prostate adverse event analysis                                                                                                                                                                                                                                                                                          
   PSA change                                                                   ×                                                                              ×                             ×                                                            ×                                    ×                ×    ×     
   Prostate volume                                                              ×                                                                              ×                             ×                                                                                            ×    ×                ×          ×
   IPSS                                         ×                                                                                                              ×                             ×                                                                                            ×    ×                ×          ×
   Abnormal PSA                                 ×                                                                                                              ×                                                           ×                              ×                                          ×    ×                ×
   Prostate biopsy                              ×                                                                            ×                                                                                             ×                              ×                                          ×          ×          ×
   Prostate cancer                              ×                                                                            ×                                                                                             ×                              ×                                          ×          ×    ×     

X indicates if Yes or No. PSA: prostatic specific antigen, IPSS: international prostatic symptoms score.
